Opinion|Videos|October 25, 2024
Timing and Urgency Considerations in SCLC
Key Takeaways
- Early initiation of immunotherapy in SCLC, often with chemotherapy, maximizes therapeutic benefits and leverages potential synergistic effects.
- Inpatient versus outpatient immunotherapy administration depends on patient stability, treatment complexity, and resource availability.
Panelists discuss how to determine the optimal timing for initiating immunotherapy in patients with small cell lung cancer (SCLC), considering the pros and cons of inpatient vs outpatient administration, while also addressing the unique barriers to diagnosing and treating SCLC compared with non–small cell lung cancer and exploring strategies to overcome these challenges.
Advertisement
Episodes in this series
What is optimal timing for starting immunotherapy in patients with small cell lung cancer (SCLC)? What are the considerations when deciding on whether to administer immunotherapy in the inpatient or outpatient setting?
What are barriers to diagnosing and treating SCLC compared with non– small cell lung cancer, and how can they be overcome?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5